RxDoctor Payments Data

Janet Tamai, DO

Neurology · Kingston, NYNPI 1548259112

Payments from drug & device makers

$8,674in general payments, 2019–2025

Across 64 payments — averaging $135.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$8K
  • AbbVie$704
  • Genentech USA, Inc.$78
  • Harmony Biosciences LLC$65
  • SK Life Science, Inc.$56
  • E.r. Squibb & Sons, L.L.C.$39
  • plus $100 from 4 others

What the payments were for

  • Food & beverage$1,14090%
  • Education$12610%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,674 in reported general payments places this provider in the 70th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$184,670
Medicare patients
670
Services billed
3,457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex Pen (4 Pack)Interferon Beta-1a30$301,076
TecfideraDimethyl Fumarate17$237,376
EpidiolexCannabidiol (Cbd)23$165,683
Gamunex-CImmune Globul G/Gly/Iga Avg 4616$137,239
Plegridy PenPeginterferon Beta-1a17$133,102
FingolimodFingolimod Hcl13$129,534
RebifInterferon Beta-1a/Albumin13$126,872
Dimethyl Fumarate34$123,368
BetaseronInterferon Beta-1b13$122,928
Rebif RebidoseInterferon Beta-1a/Albumin11$112,061
LamictalLamotrigine62$83,880
CopaxoneGlatiramer Acetate12$69,282
Nurtec OdtRimegepant Sulfate39$64,716
KeppraLevetiracetam27$56,460
NayzilamMidazolam22$42,359

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Namzaric$704$75,14161 claims
SK Life Science, Inc.Xcopri$56$26,84021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,623 neurology providers in New York.

Other neurology in Kingston

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →